NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157181&from=4CLASS PERIOD: April 29, ...

Core Insights - NodThera has appointed Dr. Jyothis George as Chief Medical Officer, effective immediately, to lead the clinical advancement of its NLRP3 inflammasome inhibitor portfolio [1][4][5] Company Overview - NodThera is a clinical-stage biotech focused on developing brain-penetrant NLRP3 inflammasome inhibitors for chronic inflammatory diseases, with two lead clinical candidates showing potentially best-in-class profiles [6] - The company is backed by prominent investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures, and Sofinnova Partners [6] Leadership Experience - Dr. Jyothis George brings extensive experience in cardiometabolic drug development, having previously served as Global Medical Vice President at Amgen, where he led strategic planning for obesity treatments [2][3] - His past roles include Corporate Vice President at Novo Nordisk, where he oversaw key clinical trials for drugs like semaglutide, and Global Head of Clinical Development at Boehringer Ingelheim, where he managed pivotal programs for empagliflozin and linagliptin [3] Strategic Vision - The appointment of Dr. George is expected to enhance NodThera's clinical development efforts, leveraging his expertise in regulatory success and landmark trials to advance the company's innovative therapies [4][5] - Dr. George expressed enthusiasm about transforming treatments for diseases linked to chronic low-grade inflammation, aiming to restore metabolic balance for patients [4]

Core Viewpoint - Novo Nordisk's shares have dropped by 52% over the past year, presenting a potential buying opportunity for investors due to its strong market position and growth prospects in diabetes and weight management treatments [1][4]. Company Overview - Novo Nordisk is a leader in developing diabetes treatments, holding a 33.3% market share in this sector as of February [2]. - The company has a long history of attracting top talent and consistently innovating in diabetes care [2]. Recent Challenges - The significant drop in share price is attributed to disappointing financial results and clinical progress, which did not meet the high expectations set by the company's valuation metrics [4]. - Despite reporting effective phase 3 results for CagriSema, an investigational weight management drug, the results fell short of management's expectations, leading to investor dissatisfaction [5]. Pipeline and Growth Potential - Novo Nordisk's pipeline remains robust, with several promising candidates in development, including Amycretin, which is in late-stage studies [6]. - The company is also diversifying its portfolio by developing treatments for rare diseases and neurological disorders, which could enhance its long-term growth prospects [8]. Financial Performance - In the first quarter, net sales grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion), and net profit increased by 14% year over year to $4.5 billion [9]. - The forward price-to-earnings (P/E) ratio has decreased to 16.9, which is slightly above the healthcare industry's average of 16.2 and lower than the S&P 500's 22.3 [10]. Future Outlook - The company is expected to make significant clinical and regulatory progress, potentially launching blockbuster medications in the next six years [13]. - Continued strong financial results and dividend increases are anticipated, with a compound annual growth rate of 12.2% needed for the stock to double in value over the next six years [14].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of securities law violations related to misleading statements and the promotion of unsafe products [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [5][6]. Group 2: Impact on Stock Price - Following Novo Nordisk's announcement of ending its partnership with Hims due to legal violations, Hims' stock price dropped by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [6]. Group 3: Call for Information - Faruqi & Faruqi encourages individuals with information regarding Hims' conduct, including whistleblowers and former employees, to come forward [8].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy on its platform, which contains the active ingredient semaglutide [3]. Group 3: Allegations of Misrepresentation - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. Group 4: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the company's stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Group 1 - Novo Nordisk, a leader in diabetes and weight loss drugs, has underperformed the S&P 500 index since March 30, 2025 [1] - The author has a long position in Novo Nordisk shares, indicating a belief in the company's potential [1] Group 2 - The article reflects a broader investment strategy that includes a focus on technology companies and opportunities in crypto, while also considering global markets [1]

RADNOR, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is Augus ...

Core Insights - Novo Nordisk primarily generates revenue from its GLP-1 injections, Ozempic and Wegovy, which have seen increased demand due to expanded prescriptions and label changes [1][2] Revenue Performance - In Q1 2025, Ozempic sales reached DKK 32.7 billion (up 15%) and Wegovy sales were DKK 17.4 billion (up 83%), together accounting for approximately 66% of total revenues [2][9] - The growth rates of these drugs were impacted by the presence of compounded GLP-1s in the market [2] Market Strategy - Novo Nordisk successfully removed semaglutide drugs from the FDA's shortage list and advocated for a federal ban on mass compounding, limiting unauthorized versions in the U.S. market [3] - The company is enhancing Wegovy access through initiatives like NovoCare Pharmacy and exclusive formulary coverage with CVS Caremark, alongside international expansion [3] Future Growth Prospects - Upcoming label expansions for Ozempic and Wegovy, including new indications and formulations, are expected to drive continued growth [4] - Novo Nordisk is addressing supply constraints by increasing manufacturing capacity, while also benefiting from its oral T2D drug Rybelsus and a portfolio of insulin and rare disease treatments [4] Competitive Landscape - Eli Lilly is a significant competitor in the obesity market with its tirzepatide products, Mounjaro and Zepbound, which generated combined sales of $6.15 billion in Q1 2025, representing about 48% of Lilly's total revenues [5] - Other companies, such as Viking Therapeutics, are advancing in the development of GLP-1-based candidates, with ongoing late-stage studies for their investigational obesity drug VK2735 [6] Stock Performance and Valuation - Year-to-date, Novo Nordisk shares have declined by 24.1%, underperforming the industry and the S&P 500 [7] - The company's shares currently trade at a forward price/earnings ratio of 15.14, slightly above the industry average of 15.04, but significantly below its five-year mean of 29.25 [11] Earnings Estimates - Earnings estimates for 2025 have improved from $3.84 to $3.98 per share over the past 60 days, while 2026 estimates have decreased from $4.64 to $4.57 [14] - The stock's return on equity over the trailing 12 months is 80.95%, outperforming the large drugmaker industry average of 33.55% [18]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit includes claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, which contains the active ingredient semaglutide [3]. Group 3: Allegations and Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming compliance with FDA regulations regarding the sale of compounded semaglutide [4]. - Following Novo Nordisk's termination of the partnership due to Hims & Hers' deceptive practices, the company's stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

Core Insights - Fangzhou Inc. has signed a Memorandum of Understanding with Novo Nordisk to collaborate on managing chronic diseases like diabetes and obesity using AI and innovative healthcare solutions [1][3][4] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, with 49.2 million registered users and 223,000 physicians as of December 31, 2024 [5] Collaboration Details - The partnership aims to leverage Novo Nordisk's expertise in diabetes and obesity treatment alongside Fangzhou's smart healthcare ecosystem to create a comprehensive health management service [3][4] - The collaboration will focus on medication guidance, reminders, efficacy tracking, and health education, shifting from a "disease-centered" to a "health-centered" model [3][4] Future Goals - Both companies aim to enhance public awareness of diabetes and obesity and implement early screening, diagnosis, and treatment within smart healthcare environments [4] - The partnership is expected to explore further innovative collaborations in the digital transformation of the medical industry, contributing to the "Healthy China 2030" strategic objectives [4]